Please use this identifier to cite or link to this item: http://dspace.iitrpr.ac.in:8080/xmlui/handle/123456789/1384
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMayank-
dc.contributor.authorSingh, M.-
dc.contributor.authorKaur, N.-
dc.contributor.authorGarg, N.-
dc.contributor.authorSingh, N.-
dc.date.accessioned2019-11-25T13:00:20Z-
dc.date.available2019-11-25T13:00:20Z-
dc.date.issued2019-11-25-
dc.identifier.urihttp://localhost:8080/xmlui/handle/123456789/1384-
dc.description.abstractIn this paper, we have established methylenebis (4-hydroxy-2H-chromen-2-one) as a promising anticancer scaffold with kinesin spindle protein (KSP) inhibitory activity under malignant condition. A series of biscoumarin derivatives (MN1 to MN30) with different substituent were synthesized, and their anticancer activity was explored. Six biscoumarin derivatives that were found active were further selected to formulate organic nanoparticles (ONPs). Anticancer activity of both the forms (viz conventional and ONPs) was compared. MN30 was found most potent whereby MN10 showed good anticancer activity in both, i.e., conventional and ONP form; the structural activity relationship (SAR) study has been established. Computational investigation revealed biscoumarin scaffold as a suitable pharmacophore to bind against KSP protein. Molecular dynamics simulation studies revealed protein-ligand stability and dynamic behavior of biscoumarin-KSP complex. Finally, accruing signal transduction model was formulated to explain the observed MTT trend of conventional and ONP form. The model seems useful towards solving population specific varied results of chemotherapeutic agents. According to the model, MN10 and MN30 derivatives have good pharmacodynamics inertia and therefore, both the molecules were able to provide dose-dependent cytotoxic results.en_US
dc.language.isoen_USen_US
dc.subjectAnticanceren_US
dc.subjectBiscoumarinen_US
dc.subjectKinesin spindle proteinen_US
dc.subjectChemotherapeuticen_US
dc.subjectPharmacodynamics inertiaen_US
dc.titleAnticancer SAR establishment and novel accruing signal transduction model of drug action using biscoumarin scaffolden_US
dc.typeArticleen_US
Appears in Collections:Year-2019

Files in This Item:
File Description SizeFormat 
Full Text.pdf2.45 MBAdobe PDFView/Open    Request a copy


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.